Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

NCT06645704 is registered in ClinicalTrials.gov with Escient Pharmaceuticals, Inc as lead sponsor.

NCT NCT06645704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06645704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration
Lead sponsor
Escient Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2024
Completion date
December 10, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants